{"id":"lu-177-pnt2002","safety":{"commonSideEffects":[{"rate":null,"effect":"Hematologic toxicity (anemia, thrombocytopenia, leukopenia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Renal toxicity"}]},"_chembl":{"chemblId":"CHEMBL4297545","moleculeType":"Protein","molecularWeight":"1609.57"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"PNT2002 is a somatostatin receptor 2-targeted radiopharmaceutical that binds to SSTR2-expressing neuroendocrine tumors and delivers localized beta radiation via lutetium-177. This theranostic approach allows both imaging and therapeutic targeting of SSTR2-positive tumors, with the radioactive payload inducing DNA damage and cell death in tumor cells while minimizing systemic exposure.","oneSentence":"[Lu-177]-PNT2002 is a lutetium-177 labeled radioligand that targets somatostatin receptor 2 (SSTR2) on neuroendocrine tumor cells, delivering targeted radiation therapy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:49:36.430Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)"},{"name":"SSTR2-positive neuroendocrine tumors"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["[Lu-177]-PSMA-I&T","LY4187525"],"phase":"phase_3","status":"active","brandName":"[Lu-177]-PNT2002","genericName":"[Lu-177]-PNT2002","companyName":"POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company","companyId":"point-biopharma-a-wholly-owned-subsidiary-of-eli-lilly-and-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"[Lu-177]-PNT2002 is a lutetium-177 labeled radioligand that targets somatostatin receptor 2 (SSTR2) on neuroendocrine tumor cells, delivering targeted radiation therapy. Used for Gastroenteropancreatic neuroendocrine tumors (GEP-NETs), SSTR2-positive neuroendocrine tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}